HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1

Vaccine

Volumn 24, Issue 21, 2006, Pages 4541-4547

  Starodubova, Elizaveta ^a,b   Boberg, Andreas ^b,c   Kashuba, Elena V ^c   Wahren, Britta ^b,c   Karpov, Vadim ^a   Isaguliants, Maria ^b  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA vaccine; Drug resistance; HIV 1; Proteasome; Reverse transcriptase

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EPOXOMICIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN DEGRADATION; VACCINATION; WESTERN BLOTTING;

AIDS VACCINES; BASE SEQUENCE; CELL LINE; DNA PRIMERS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROLYSIS; ORNITHINE DECARBOXYLASE; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 33646822500     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.020     Document Type: Article

References (32)

1. Kloetzel P.M. Antigen processing by the proteasome. Nature Rev 2 (2001) 179-187
2. Niedermann G., Geier E., Lucchiari-Hartz M., Hitziger N., Ramsperger A., and Eichmann K. The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. Immunol Rev 172 (1999) 29-48
3. Mulder L.C., and Muesing M.A. Degradation of HIV-1 integrase by the N-end rule pathway. J Biol Chem 275 38 (2000) 29749-29753
4. Fujita M., Akari H., Sakurai A., Yoshida A., Chiba T., Tanaka K., et al. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 6 9 (2004) 791-798
5. Parissi V., Caumont A., de Soultrait V.R., Desjobert C., Calmels C., Fournier M., et al. The lethal phenotype observed after HIV-1 integrase expression in yeast cells is related to DNA repair and recombination events. Gene 322 (2003) 157-168
6. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173 6 (2004) 3838-3843
7. Roeth J.F., Williams M., Kasper M.R., Filzen T.M., and Collins K.L. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol 167 5 (2004) 903-913
8. Kasper M.R., Roeth J.F., Williams M., Filzen T.M., Fleis R.I., and Collins K.L. HIV-1 Nef disrupts antigen presentation early in the secretory pathway. J Biol Chem 280 13 (2005) 12840-12848
9. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., et al. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 78 3 (2004) 1324-1332
10. Singh R.A., and Barry M.A. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol 173 7 (2004) 4387-4393
11. Tang J.W., and Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 30 1 (2004) 1-10
12. Schmitt M., Harrer E., Goldwich A., Bauerle M., Graedner I., Kalden J.R., et al. Specific recognition of lamivudine-resistant HIV by cytotoxic T lymphocytes. AIDS 14 6 (2000) 653-658
13. Mason R.D., Bowmer M.I., Howley C.M., Gallant M., Myers J.C., and Grant M.D. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 172 11 (2004) 7212-7219
14. Isaguliants M.G., Belikov S.V., Starodubova E.S., Gizatullin R.Z., Rollman E., Zuber B., et al. Mutations conferring drug resistance affect eukaryotic expression of HIV type 1 reverse transcriptase. AIDS Res Hum Retroviruses 20 2 (2004) 191-201
15. Isaguliants M.G., Pokrovskaya K., Kashuba V.I., Pokholok D., Hinkula J., Wahren B., et al. Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. FEBS Lett 447 (1999) 232-236
16. Isaguliants M.G., Zuber B., Boberg A., Sjustrand D., Belikov S.V., Rollman E., et al. Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in mouse model. Vaccine 22 (2004) 1810-1819
17. Varshavsky A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci USA 93 22 (1996) 12142-12149
18. Chateau M.T., Robert-Hebmann V., Devaux C., Lazaro J.B., Canard B., and Coux O. Human monocytes possess a serine protease activity capable of degrading HIV-1 reverse transcriptase in vitro. Biochem Biophys Res Commun 285 4 (2001) 863-872
19. Sewell A.K., Price D.A., Teisserenc H., Booth Jr. B.L., Gileadi U., Flavin F.M., et al. IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J Immunol 162 12 (1999) 7075-7079
20. Lee D.H., and Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8 10 (1998) 397-403
21. Groll M., and Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695 1-3 (2004) 33-44
22. Riviere Y., and Buseyne F. Cytotoxic T lymphocytes generation capacity in early life with particular reference to HIV. Vaccine. 16 14-15 (1998) 1420-1422
23. Bernard N.F., Pederson K., Chung F., Ouellet L., Wainberg M.A., and Tsoukas C.M. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 12 16 (1998) 2125-2139
24. Brander C., and Riviere Y. Early and late cytotoxic T lymphocyte responses in HIV infection. AIDS 16 Suppl. 4 (2002) S97-S103
25. Keoshkerian E., Ashton L.J., Smith D.G., Ziegler J.B., Kaldor J.M., Cooper D.A., et al. Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression. J Med Virol 71 4 (2003) 483-491
26. Tobery T., and Siliciano R.F. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 162 2 (1999) 639-642
27. Wong S.B., Buck C.B., Shen X., and Siliciano R.F. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J Immunol 173 5 (2004) 3073-3083
28. Marques Jr. E.T., Chikhlikar P., de Arruda L.B., Leao I.C., Lu Y., Wong J., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 278 39 (2003) 37926-37936
29. Rosenberg-Hasson Y., Bercovich Z., Ciechanover A., and Kahana C. Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent. Eur J Biochem 185 2 (1989) 469-474
30. Murakami Y., Matsufuji S., Kameji T., Hayashi S., Igarashi K., Tamura T., et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360 6404 (1992) 597-599
31. Murakami Y., Matsufuji S., Miyazaki Y., and Hayashi S. Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells. J Biol Chem 267 19 (1992) 13138-13141
32. Corish P., and Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 12 (1999) 1035-1040